Advertisement

Radioimmunodetection of Cancer

  • E. Edmund Kim

Abstract

Radiolabeled monoclonal antibodies have gained widespread acceptance as relatively receptor-specific radiopharmaceuticals for clinical applications. Over the past decade, several clinical trials have demonstrated the ability of radiolabeled antibodies to localize certain cancers with sensitivities and specificities comparable to and, in some instances, superior to conventional diagnostic modalities. The U.S. Food and Drug Administration (FDA) has approved four radiolabeled monoclonal antibody conjugates for human use: satumormab pendetide (OncoScint; Cytogen) for colorectal and ovarian cancer; arcitumomab (CEA-Scan; Immunomedics) for colorectal cancer; capromab pendetide (ProstaScint; Cytogen) for prostate carcinoma, and nofetumomab merpentan (Verluma; DuPont Radiopharrmaceuticals) for small-cell lung carcinoma.

Keywords

Prostate Cancer Ovarian Cancer Hepatic Metastasis Germ Cell Tumor Medullary Thyroid Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Goldenberg DM, Larson SM. Radioimmunodetection in cancer identification. J Nucl Med 1992;33:803–814.PubMedGoogle Scholar
  2. 2.
    Zuckier LS, DeNardo GL. Trials and tribulations: oncological antibody imaging comes to the fore. Semin Nucl Med 1997;27:10–29.PubMedCrossRefGoogle Scholar
  3. 3.
    Collier BD, Abdel-Nabi HH, Doerr RJ, et al. Immunoscintigraphy with In-111 CYT- 103 in the management of colorectal carcinoma: a comparison with CT. Radiology 1992;185:179–186.PubMedGoogle Scholar
  4. 4.
    Serafini AN. From monoclonal antibodies to peptides and molecular recognition units. An overview. J Nucl Med 1993;34:533–536.Google Scholar
  5. 5.
    Landis SH, Murray T, Bodden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49:8–31.PubMedCrossRefGoogle Scholar
  6. 6.
    Steele GB Jr. The National Cancer Data Base report on colorectal cancer. Cancer (Phila) 1994; 74:1979–1989.CrossRefGoogle Scholar
  7. 7.
    Galandiuk S, Wieand HS, Moertelo CG, et al. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 1992;174:27–32.PubMedGoogle Scholar
  8. 8.
    Doerr RJ, Kulaylat MN, Abdel-Nabi H. Imaging strategies in hepatic metastases from colorectal carcinoma. J Hepato-Biliary-Pancreatico Surg 1995;2:126–133.CrossRefGoogle Scholar
  9. 9.
    Nabi H, Doerr RJ, Chan H-W, et al. In-111-labeled monoclonal antibody immunoscintigra- phy in colorectal carcinoma: safety, sensitivity, and preliminary clinical results. Radiology 1990; 175:163–171.PubMedGoogle Scholar
  10. 10.
    Thor A, Ohuchi N, Szpak CA, et al. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res 1986;46:3118–3124.PubMedGoogle Scholar
  11. 11.
    Rodwell JD, Alvarez VL, Lee C, et al. Sitespecific covalent modification of monoclonal antibodies: in vitro and in vivo evaluations. Proc Natl Acad Sci USA 1986;83:2632–2636.PubMedCrossRefGoogle Scholar
  12. 12.
    Doerr RJ, Abdel-Nabi H, Krag D, et al. Radiolabeled antibody imaging in the management of colorectal cancer. Results of a multicenter clinical study. Ann Surg 1991;214:118–124.PubMedCrossRefGoogle Scholar
  13. 13.
    Markowitz A, Saleemi K, Freeman LM, et al. Role of In-111-labeled CYT- 103 immunoscintigraphy in the evaluation of patients with recurrent colorectal cancer. Clin Nucl Med 1993;18: 685–700.PubMedCrossRefGoogle Scholar
  14. 14.
    Doerr RJ, Abdel-Nabi H, Krag D, et al. Radiolabeled antibody imaging in the management of colorectal cancer. Ann Surg 1991;214:118–124.PubMedCrossRefGoogle Scholar
  15. 15.
    Moffat FL Jr, Pinsky CM, Hammershaimb L, et al. Clinical utility of external immunoscitigraphy with the IMMU-4 Tc-99m Fab’ antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum. Results of a pivotal phase III trial. J Clin Oncol 1996;14: 2295–2305.PubMedGoogle Scholar
  16. 16.
    Hughes K, Pinsky CM, Petrelli NJ, et al. Use of carcinoembryonic antigen radioimmunodetection and computed tomography for predicting the resectability of recurrent colorectal cancer. Ann Surg 1997;226:621–631.PubMedCrossRefGoogle Scholar
  17. 17.
    Gulec SA, Serafini AN, Moffat FL, et al. Radioimmuno-scintigraphy of colorectal carcinoma using Tc-99m human monoclonal antibody 88BV59H21–2. Cancer Res 1995;55:5774–5776.Google Scholar
  18. 18.
    Mettlin C, Jones GW, Murphy GP. Trends in prostate cancer care in the United States, 1974–1990. Observation from the patient care evaluation studies of the American College of Surgeons Commission on Cancer. Cancer J Clin 1993;43:83–91.CrossRefGoogle Scholar
  19. 19.
    McNeil JE. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer (Phila) 1990;66:1225–1233.CrossRefGoogle Scholar
  20. 20.
    Golimbu M, Morales P, Al-Askaris et al. CAT scanning in staging of prostatic cancer. Urology 1981;18:305–308.PubMedCrossRefGoogle Scholar
  21. 21.
    Babaian RJ, Lamki LM. Radioimmunoscintigraphy of prostate cancer. Semin Nucl Med 1989; 19:309–321.PubMedCrossRefGoogle Scholar
  22. 22.
    Schellmanner PF, Wright GL Jr. Biomolecular and clinical characteristics of PSA and other candidate prostate tumor markers. Urol Clin North Am 1993;20:597–606.Google Scholar
  23. 23.
    Burgers JK, Hinkle GH, Haseman MK. Monoclonal antibody imaging of recurrent and metastatic prostate cancer. Semin Urol 1995;13:102–112.Google Scholar
  24. 24.
    Babaian RJ, Sayer J, Podoloff DA, et al. Radioimmunoscintigraphy of pelvic lymph nodes with In-111 MoAb CTY-356. J Urol 1994;152:1952–1955.PubMedGoogle Scholar
  25. 25.
    Kahn D, Williams RD, Seldin DW, et al. Radioimmunoscintigraphy with In-111 CYT-356 for the detection of occult prostate cancer recurrence. J Urol 1994;152:1490–1495.PubMedGoogle Scholar
  26. 26.
    Breitz HB. Imaging lung cancer with radiolabeled antibodies. Semin Nucl Med 1993;23: 127–132.PubMedCrossRefGoogle Scholar
  27. 27.
    Vansant JP. Staging lung carcinoma with Tc-99m monoclonal antibody. Clin Nucl Med 1992;17: 431–438.PubMedCrossRefGoogle Scholar
  28. 28.
    Kramer EL, Noz, ME, Liebes L, et al. Radioimmuno-detection of non-small cell lung cancer using Tc-99m anticarcinoembryonic antigen IMMU-4 Fab’ fragment. Cancer (Phila) 1994;73:890–895.CrossRefGoogle Scholar
  29. 29.
    Goldenberg DM, Kim EE, DeLand FH, et al. Radioimmunodetection of cancer with radioactive antibodies to carcinoembryonic antigen. Cancer Res 1980;40:2984–2992.PubMedGoogle Scholar
  30. 30.
    Lamki LM, Buzdar AU, Singletary SE, et al. In-111 B72.3 monoclonal antibody in the detection and staging of breast cancer. J Nucl Med 1991;32:1326–1332.PubMedGoogle Scholar
  31. 31.
    Crippa F, Agresto R, Bombardieri E, et al. Preliminary results of preoperative axillary radioimmunoscintigraphy with In-111 B72.3 in breast cancer. Int J Oncol 1995;6:791–795.PubMedGoogle Scholar
  32. 32.
    Nabi H. Antibody imaging in breast cancer. Semin Nucl Med 1997;27:30–34.PubMedCrossRefGoogle Scholar
  33. 33.
    Pauletti G, Godolphin W, Pres MF, et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996;12:63–72.Google Scholar
  34. 34.
    Allan SM, Dean CJ, Eccles S, et al. Clinical radioimmunolocalization with a rat monoclonal antibody directed against c-erbB-2. Cell Biophys 1994;24–25:93–98.PubMedGoogle Scholar
  35. 35.
    Waxman AD. The role of Tc-99m methoxyisobutyliso-nitride in imaging breast cancer. Semin Nucl Med 1997;27:40–54.PubMedCrossRefGoogle Scholar
  36. 36.
    Goldenberg DM, Nabi HA. Breast cancer imaging with radiolabeled antibodies. Semin Nucl Med 1999;24:41–48.Google Scholar
  37. 37.
    Rubin SC, Lewis JL Jr. Second-look surgery in ovarian carcinoma. Crit Rev Oncol Hematol 1988;8:75–91.PubMedCrossRefGoogle Scholar
  38. 38.
    Surwit EA, Childers JM, Krag DN, et al. Clinical assessment of In-111 CTY-103 immunoscintigraphy in ovarian cancer. Gynecol Oncol 1993;48: 285–292.PubMedCrossRefGoogle Scholar
  39. 39.
    Alexander C, Villena-Heinsen CE, Trampert L, et al. Radioimmunoscintigraphy of ovarian tumors with Tc-99m-labeled MoAb-170: first clinical experiences. Eur J Nucl Med 1995; 22:645–651.PubMedCrossRefGoogle Scholar
  40. 40.
    Juweid M, Sharkey RM, Behn T, et al. Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen. J Clin Oncol 1996;14:1209–1217.PubMedGoogle Scholar
  41. 41.
    Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131 anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996;14:1974–1981.PubMedGoogle Scholar
  42. 42.
    Blend MJ, Hyun H, Kozloff M, et al. Improved staging of B-cell non-Hodgkin’s lymphoma patients with Tc-99m-labeled LL2 monoclonal antibody fragment. Cancer Res 1995;55:5764–5770.Google Scholar
  43. 43.
    Jadadpour N. Current status of tumor markers in testicular cancer. Eur Urol 1992;21:34–36.Google Scholar
  44. 44.
    Fossa S, Qvist H, Stenwig A, et al. Is postchemotherapy retroperitoneal surgery necessary in patients with non-seminomatous testicular cancer and minimal residual tumor masses? J Clin Oncol 1992;10:569–573.PubMedGoogle Scholar
  45. 45.
    Kim EE, DeLand FH, Nelson MO, et al. Radioimmunodetection of cancer with radiolabeled antibodies to a-fetoprotein. Cancer Res 1980;40:3008–3012.PubMedGoogle Scholar
  46. 46.
    Kasi LP, Kim EE, Diaz M, et al. Pharmakokinetic evaluation of Tc-99m anti-AFP Fab’ in patients with germ cell tumors. J Nucl Med 1994;35:11–12 (abstract).Google Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • E. Edmund Kim

There are no affiliations available

Personalised recommendations